Sign in

You're signed outSign in or to get full access.

Colleen Cousy

Vice President and Senior Equity Research Analyst at Baird Financial Group, Inc.

Colleen Kusy is a Vice President and Senior Equity Research Analyst at Baird specializing in biotechnology sector research with an emphasis on smid-cap companies, oncology, and rare diseases. Since joining Baird in 2014, she has developed expertise in evaluating diverse therapeutic areas and is recognized for her coverage of leading firms in the retinal treatment space, with a reputation for effective communication of investment insights. In 2023, she was named a 'Rising Star of Equity Research' by Business Insider for her impact on the industry, having progressed from a business analyst to her current senior leadership role. Kusy holds a CFA designation and earned a BBA in Finance as well as a BA in French and Francophone Studies from Villanova University.

Colleen Cousy's questions to Mersana Therapeutics (MRSN) leadership

Question · Q2 2025

An analyst on behalf of Colleen Cousy at Baird asked about the enrollment rate for EMILY compared to internal expectations and also inquired about the enrollment progress for the HER2-targeting ADC, XMT-2056.

Answer

President and CEO Dr. Martin Huber expressed that EMILY enrollment is progressing 'very well' for a biomarker-selected study and that no additional sites are needed for the expansion phase. For XMT-2056, he pointed to the recent $15 million development milestone from GSK as evidence that enrollment has picked up and the program is 'chugging along,' while reiterating that the company is not committing to sharing dose-escalation data this year.

Ask follow-up questions

Fintool

Fintool can predict Mersana Therapeutics logo MRSN's earnings beat/miss a week before the call